CAR T-cell development in Europe – where are we in CLL?
Identifying patients at different risk of relapse in childhood acute lymphoblastic leukemia (ALL)
'Off the shelf' virus-specific T cells
Inotuzumab and blinatumomab: the most exciting ALL news from EHA 2017
Progress in the development of treatments for leukemia